Skip to main content

Advertisement

SpringerLink
Log in

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

The combination of 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (I-OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated if the drug delivery rate was chronomodulated according to circadian rhythms rather than constant. The aim of the present study was to define the feasibility and efficacy of XELOX administered through a new chronomodulated schedule in untreated advanced colorectal cancer (CRC) patients.

Methods

Chemotherapy-naive patients with advanced CRC were considered eligible for the study accrual. Treatment: oxaliplatin 70 mg/m2 continuous infusion (c.i.) for 12 h (8:00 a.m. to 8:00 p.m.) days 1, 8 plus chronomodulated oral capecitabine 1,750 mg/m2/die (h 8:00 a.m. 25% of total dose; h 6:00 p.m. 25% of total dose; h 11:00 p.m. 50% of total dose), days 1–14 every 21 days.

Results

Forty-six patients were evaluated for safety and efficacy (male/female, 20/26). Median age was 64 years (range 28–77 years). Median Eastern Cooperative Oncology Group performance status (PS) was 0 (range 0–1). A total of 324 cycles have been administered: median per patient 6 (range 3–10 courses). Median number of metastatic sites was 1. Metastatic sites distribution was as follows: liver (65.2%), lung (34.8%), and nodes (32.6%). Median follow-up was 14 months (range 6.0–40.3 months). In an intent-to-treat efficacy analysis, objective response and stable disease were recorded in 27 (58.6%) and in 16 patients (34.9%), respectively. The median response duration was 8.0 months (95% CI; 5.03–10.96 months). The median time to progression (TTP) was 9.0 months (95% CI; 6.47–11.52 months). The overall survival (OS) was not reached, with a median value > 24 months (95% CI; 23.66–36.30 months). The grade 3 toxicities were diarrhea (8.7%), liver toxicity (13.1%), fatigue (8.7%), neurotoxicity (2.2%), neutropenia (8.7%), and thrombocytopenia (2.2%).

Conclusion

This regimen resulted of particular interest for patients with untreated metastatic CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 5:15–36

    Google Scholar 

  2. Jemal A, Tiwari RC, Murray T, et al (2004) Cancer statistics 2004. CA Cancer J Clin 54:8–29

    Article  PubMed  Google Scholar 

  3. Nordic gastrointestinal Tumor adjuvant therapy group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal: a randomised trial. J Clin Oncol 10:904–911

    Google Scholar 

  4. Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM (1992) Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin Oncol 19:105–125

    PubMed  CAS  Google Scholar 

  5. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664

    PubMed  CAS  Google Scholar 

  6. Scheithauer W, Rosen H, Kornek GV, et al (1993) Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752–755

    PubMed  CAS  Google Scholar 

  7. De Gramont A, Bosset JF, Milan C, et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 2:808–815

    Google Scholar 

  8. Kohne CH, Wils J, Lorenz M, et al (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21:3721–3728

    Article  PubMed  CAS  Google Scholar 

  9. Cunningham D, Pyrhonen S, James RD, et al (1998) Randomized trial of irinotecan plus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418

    Article  PubMed  CAS  Google Scholar 

  10. Douillard JY, Cunningham D, Roth AD, et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047

    Article  PubMed  CAS  Google Scholar 

  11. Saltz LB, Cox JV, Blanke C, et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914

    Article  PubMed  CAS  Google Scholar 

  12. Misset JL, Bleiberg H, Sutherland W, et al (2000) Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 35:75–93

    PubMed  CAS  Google Scholar 

  13. Raymond E, Faivre S, Woynarowski JM, Chaney SG (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25:4–12

    PubMed  CAS  Google Scholar 

  14. De Gramont A, Figer A, Seymour M, et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  15. Goldberg RM, Morton RF, Sargent DJ, et al (2003) N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer. Updated efficacy and quality of life (QOL) data from an intergroup study. Proc ASCO 22:252

    Google Scholar 

  16. Diaz-Rubio E, Evans TR, Tabemero J, et al (2002) Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumours. Ann Oncol 13:558–565

    Article  PubMed  CAS  Google Scholar 

  17. Miwa M, Ura M, Nishida M, et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281

    Article  PubMed  CAS  Google Scholar 

  18. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85–104

    Article  PubMed  CAS  Google Scholar 

  19. Hoff PM, Ansari R, Batist G, et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292

    PubMed  CAS  Google Scholar 

  20. Diaz-Rubio E, Evans TR, Tabernero J, et al (2002) Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumours. Ann Oncol 13:558–565

    Article  PubMed  CAS  Google Scholar 

  21. Borner MM, Dietrich D, Stupp R, et al (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:1759–1766

    Article  PubMed  CAS  Google Scholar 

  22. Zeuli M, Nardoni C, Pino MS, et al (2003) Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 14:1378–1382

    Article  PubMed  CAS  Google Scholar 

  23. Scheithauer W, Kornek GV, Raderer M, et al (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2:1307–1312

    Article  CAS  Google Scholar 

  24. Milano G, Chamorey AL (2002) Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 19:177–189

    Article  PubMed  CAS  Google Scholar 

  25. Garufi C, Brienza S, Pugliese P, et al (2000) Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. Anticancer Drugs 11:495–501

    Article  PubMed  CAS  Google Scholar 

  26. Mormont MC, Waterhouse J, Bleuzen P, et al (2000) Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6:3038–3045

    PubMed  CAS  Google Scholar 

  27. Giacchetti S, Perpoint B, Zidani R, et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147

    PubMed  CAS  Google Scholar 

  28. Levi F, Zidani R, Brienza S, et al (1999) A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 85:2532–2540

    Article  PubMed  CAS  Google Scholar 

  29. Rosati G, Rossi A, Tucci A, et al (2001) Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Ann Oncol 12:669–674

    Article  PubMed  CAS  Google Scholar 

  30. Santini D, Vincenzi B, La Cesa A, et al (2005) Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology 69(1):27–34

    Article  PubMed  CAS  Google Scholar 

  31. MacDonald J, Haller D, Mayer R (1995) Grading of toxicity. In: MacDonald J, Haller D, Mayer R (eds) Manual of oncologic therapeutics. Lippincott, Philadelphia, PA, pp 519–523

    Google Scholar 

  32. Thall PF, Simon R, Ellenberg SS (1989) A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45:537–547

    Article  PubMed  CAS  Google Scholar 

  33. Cassidy J, Tabernero J, Twelves C, et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084–2091

    Article  PubMed  CAS  Google Scholar 

  34. Park SH, Bang SM, Cho EK, et al (2004) First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 66:353–357

    Article  PubMed  CAS  Google Scholar 

  35. Borner MM, Bernhard J, Dietrich D, et al (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16:282–288

    Article  PubMed  CAS  Google Scholar 

  36. Borner MM, Dietrich D, Stupp R, et al (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20(1):1759–1766

    Article  PubMed  CAS  Google Scholar 

  37. Sumpter K, Harper-Wynne C, Cunningham D, et al (2003) Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution’s experience. Clin Oncol (R Coll Radiol) 15:221–226

    CAS  Google Scholar 

  38. Pfeiffer P, Hahn P, Jensen HA (2003) Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 42:832–836

    Article  PubMed  CAS  Google Scholar 

  39. Shields AF, Zalupski MM, Marshall JL, Meropol NJ (2004) Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 100:531–537

    Article  PubMed  CAS  Google Scholar 

  40. Jordan K, Kellner O, Kegel T, et al (2004) Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 4:46–50

    Article  PubMed  CAS  Google Scholar 

  41. Andrè T, Bensmaine MA, Louvet C, et al (1999) Multicentre phase II study of bimonthly high dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560–3568

    PubMed  Google Scholar 

  42. Hochster H, Chachoua A, Speyer J, et al (2003) Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 21:2703–2707

    Article  PubMed  CAS  Google Scholar 

  43. Tournigand C, Andre T, Achille E, et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237

    Article  PubMed  CAS  Google Scholar 

  44. Sorbye H, Glimelius B, Berglund A, et al (2004) Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 22:31–38

    Article  PubMed  CAS  Google Scholar 

  45. Simpson D, Dunn C, Curran M, Goa KL (2003) Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 63:2127–2156

    Article  PubMed  CAS  Google Scholar 

  46. Goldberg RM, Sargent DJ, Morton RF, et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  PubMed  CAS  Google Scholar 

  47. Cassidy J, Twelves C, Van Cutsem E, et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575

    Article  PubMed  CAS  Google Scholar 

  48. Hoff PM, Pazdur R, Lassere Y, et al (2004) Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 22:2078–2083

    Article  PubMed  CAS  Google Scholar 

  49. Scheithauer W, McKendrick J, Begbie S, et al (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14:1735–1743

    Article  PubMed  CAS  Google Scholar 

  50. Van Cutsem E, Twelves C, Cassidy J, et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, University Campus Bio-Medico, Via Emilio Longoni, 69, 00155, Rome, Italy

    Daniele Santini, Bruno Vincenzi, Gaia Schiavon, Vladimir Virzí & Giuseppe Tonini

  2. Medical Oncology, University “La Sapienza”, Rome, Italy

    Marisa Di Seri & Bruno Spalletta

  3. Surgical Oncology, University Campus Bio-Medico, Via Emilio Longoni, 69, 00155, Rome, Italy

    Marco Caricato & Roberto Coppola

Authors
  1. Daniele Santini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Vincenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gaia Schiavon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marisa Di Seri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vladimir Virzí
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bruno Spalletta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marco Caricato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roberto Coppola
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giuseppe Tonini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniele Santini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Santini, D., Vincenzi, B., Schiavon, G. et al. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol 59, 613–620 (2007). https://doi.org/10.1007/s00280-006-0302-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0302-x

Keywords

Search

Navigation